Brief: Pure Biologics Signs License Deal For Use Of Pureapta Platform in France
26/11/2021 07:29
Nov 26 (Reuters) - Pure Biologics SA PUR1.WA :
* SIGNS LICENSE DEAL WITH FRANCE-BASED NOVAPTECH SAS FOR
USE OF
PUREAPTA PLATFORM
Source text for Eikon: ID:nEM6L5Sxta
Further company coverage: PUR1.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Multiqure SA
See all newsBrief: Selvita To Expand Its Operations Through New Biological Drug Business
Brief: Pure Biologics FY Net Loss Widens To 25.6 Mln Zlotys
Brief: Pure Biologics Signs Term Sheet With ACRX Investments On Potential Financing
Brief: Pure Biologics Signs Deal For Subsidy With Poland's Medical Research Agency
Brief: Pure Biologics To Seek Extra Financing For PB003 And PB004 Projects